Small Cap Feast

24th October 2022

Dish of the day
No Joiners today
Off the menu
No leavers today
Dish Of The Day:
Eastinco Mining (ATN.L) has joined AIM
Off The Menu:
Ted Baker has left the London Stock Exchange

What’s Cooking In The IPO Kitchen?

Ithaca Energy, a UK independent exploration and production company focused on the UK North Sea, intends to join the Premium Segment of the Main Market. Ithaca Energy is one of the largest independent oil and gas companies in the UKCS, ranking 2nd by resources and 3rd by production. During the six months ended 30 June 2022, Ithaca Energy’s average daily production (oil and gas) on a net working interest basis was c. 66.7 kboe/d, the Group’s revenue was c.$1,338m, Adjusted EBITDAX was c. $907m, profit after tax was c. $1,558m.

BWP REIT, a newly formed single asset company, announces its intention to raise £35m through the issue of 35m ordinary shares at the issue price of £1 per share, to acquire Bridgewater Place, an office-led mixed use property situated in central Leeds and valued at £63m. BWP REIT will apply for listing on the Wholesale Segment of the International Property Securities Exchange (PSX). Expected 27 October 2022.
World Chess plc, a leading chess organisation, intends to join the Main Market. World Chess Plc is the holding company of a group which aims to promote the mass market appeal of chess globally through the commercial offering of chess related activities. Euro 8m to be raised. Expected November 2022.

OTAQ plc, (OTAQ.L) the technology company with three divisions: Aquaculture, Geotracking Devices and Offshore intends to delist from the Main Market and join the AQSE Growth Market. OTAQ is developing adjacent technologies to take advantage of a number of growth initiatives that will broaden the Group’s current product portfolio in the global marine aquaculture sector and facilitate entry and growth into the geotracking devices sector. Expected 9 November 2022. Raising a total of £3.6m, £2m raised.

Cooks Coffee Company ltd, an international coffee focused café chain which currently owns the Esquires Coffee and Triple Two Coffee Brands, intends to join the AQSE Growth Market. The Company is the 4th largest coffee focused café chain in the UK. Cooks Coffee is currently listed on the New Zealand Stock Exchange. Raising £1.5m through a rights issue in New Zealand and a private placement. Expected 2 November 2022.

Guanajuato Silver Company ltd, a fast growing silver producer in Mexico currently listed on the TSX Venture Exchange, intends to join the AQSE Growth Market. The Company currently owns five precious metals mines and three production facilities. GSilver is primarily focused on reactivating past producing silver and gold mines in the state of Guanajuato. Expected 25 October 2022.

TECC Capital plc, to be renamed EDX Medical Group, intends to join the AQSE Growth Market. EDX operates a molecular biology and diagnostics laboratory in Cambridge, UK, from which it performs research & development, provides Polymerase Chain Reaction (PCR) testing and genomic sequencing services, undertakes quality assurance and has established expertise in the design, development, validation and sourcing of Lateral Flow Tests on a commercial scale. Due 31 October 2022.

Streaks Gaming plc, a UK-based provider of conversational gaming products intends to join the Standard Segment of the Main Market this autumn. The flotation is expected to value Streaks at approximately £10.2m (pre-money) and will make it the first LSE-listed “pure-play” conversational gaming company. Raising between £5-10m. Delayed but due in October.

Welkin China Private Equity, newly established closed-ended investment company dedicated to investing in unquoted Chinese companies, intends to join the Premium Segment of the Main Market. The Company is targeting a raise of up to US$300m. Due 3 November 2022.

Georgina Energy, focusing on the exploration, development and monetisation of helium, hydrogen and hydrocarbon interests located in Australia intends to join AIM. Georgina Energy has two principal onshore interests: (1) Mount Winter Prospect in the Amadeus Basin in Northern Australia, which the Company has a right to earn an initial 75% interest; (2) Hussar Prospect, 100% owned by the Company, located in the Officer Basin in Western Australia. Expected late October.

Breakfast Buffet

Aferian 83p £69.4m (AFRN.L)

The B2B video streaming solutions company announces a trading update. The Amino business has experienced delays, consequently, device revenues are now expected to be approximately 10% lower than its expectation for the year ending 30 November 2022. This trend is expected to continue into the first half of FY23 as some customer inventory levels remain high to mitigate the earlier supply chain disruptions. Exit ARR and software revenue growth of approximately 15% and 5% respectively (25% and 15% on a constant currency basis) remains in line with original management expectations. The Board now expects Group adjusted operating profit for the year ending 30 November 2022 to be in the range of $7.8m to $8.8m. There will also be a one-off charge of approximately $5.5m for costs incurred in relation to an aborted significant acquisition opportunity. Net cash at 30 November 2022 is expected to be in the range of $2m net cash to $2m net debt.

Cerillion £11.20 £330.2m (CER.L)

The billing, charging and customer relationship management software solutions provider, announces a trading update for the financial year ended 30 September 2022. Revenue is expected to be marginally ahead of market expectations and adjusted profit before tax is expected to be materially ahead of the consensus forecast of £10.1m, as a result of favourable foreign exchange rates, higher resource utilisation, lower net finance costs and lower depreciation and amortisation than anticipated. Net cash at 30 September 2022 is anticipated to close at approximately £20.0m (30 September 2021: £13.2m), also ahead of market expectations.

D4t4 Solutions 240p £96.1m (D4T4.L)

The data solutions provider announces the following trading update for the six months to 30 September 2022. Results are expected to be in line with management expectations, with revenues of approximately £8.1m (H1 FY22: £7.5m) and adjusted losses before tax of approximately £1.3m (H1 FY22: profit £0.1m). Annual recurring revenue increased during the period to £15.8m (31 March 2022: £14m). Of this increase £0.4m arises from customer wins, with £1.4m from the period-end revaluation of ARR contracts in foreign currency. The cash balance at the half year end was robust at £26.2m.

Eneraqua Technologies 305p £101.3m (ETP.L)

The specialist provider of energy and water efficiency solutions, announces the award of a contract to deliver ground source heat pump systems for a new UK social housing client, to be phased over up to 3 years. This new contract win, together with other smaller recent awards across the Group, have an aggregate contract value of up to £35m. These new wins increase the order book, taking cover for its FYJan24 revenue target to 85% (from prior 72%).

Neometals 63.5p £337.6m (NMT.L)

The sustainable battery materials producer announces that the Vanadium Recovery Project (VRP1) in Pori, Finland has been granted an Environmental Permit by the Regional State Administrative Agency for Southern Finland. Permit authorises, subject to conditions, construction and operation of a vanadium recovery plant to produce supply constrained of approximately 9,000tpa vanadium pentoxide in Europe. Neometals is earning a 50% equity interest in an incorporated joint venture to develop VRP1 with an unlisted Australian mineral development company, Critical Metals Ltd.

OptiBiotix Health 17.5p £15.4m (OPTI.L)

The life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its exclusive distributor Nahdi Medical has received approval from the Saudi Food and Drug authority (SFDA) for GoFigure shakes and bars containing patented weight management aid SlimBiome®. The SFDA approval originally envisaged for early 2022, is of strategic importance as it facilitates the registration processes in the other GCC (Gulf Cooperation Council) countries. As a direct consequence, OptiBiotix has received the first purchase order from Nahdi.

Petrel Resources 1.35p £2.1m (PET.L)

The oil exploration company announce that it has arranged a placing with Monecor (London) Ltd trading as OvalX to raise £250k before expenses via the issue of 20,833,333 new ordinary shares at a price of 1.2p per Placing Share. Each Placing Share has 1 warrant attached with the right to subscribe for one new ordinary share at 1.8p per new ordinary share for a period of 2 years. The proceeds of the placing will serve as additional working capital, as Petrel’s board continues to assess new projects in Iraq and advance its Ghanaian interests.

Sareum Holdings* 147.5p £100.4m (SAR.L)

The biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces its audited results for the year ended 30 June 2022. Sareum reported a loss on ordinary activities of £2.2m (2021: loss of £1.5m), reflecting the increased R&D investment required for late preclinical development. Throughout the period £3.6m was raised through subscriptions. Cash at the bank as of 30 June 2022 was £4.3m. Post period, a Clinical Trial Application for a Phase 1a/b study with SDC-1801 has been submitted to the Medicines and Healthcare products Regulatory Agency (MHRA). Sareum plans to initiate Phase 1 clinical trials by the end of 2022 in healthy subjects, with a study in psoriasis patients planned for 2023.

SDI Group 117p £179.4m (SDI.L)

The designer and manufacturer of scientific and technology products for digital imaging, sensing and control applications, announces on 21 October 2022 the acquisition of Fraser Anti-Static Techniques Limited (Fraser), a UK manufacturer of anti-static equipment. Total consideration is estimated at £13.0m, net of £3.9m excess cash acquired, consisting of initial consideration of £15.4m (including £3.4m of excess cash) and the balance payment of £1.5m in cash (including £0.5m of excess cash) shortly after completion, dependent on the net assets of Fraser delivered at completion. The net assets include freehold ownership of Fraser’s three manufacturing units, valued at approximately £1.76m. The acquisition is expected to be enhancing in the current year.

ValiRx 15.5p £14.0m (VAL.L)

The life science company focusing on early-stage cancer therapeutics and women’s health, announces today the formation of a new partially-owned subsidiary company, Cytolytix Limited, and that Cytolytix has signed an IP License Agreement with King’s College London. Cytolytix has been established to progress the triple negative breast cancer project, CLX001, through preclinical development to a stage of readiness for clinical trials. ValiRx holds 60% of the shares in Cytolytix. The remaining 40% is split between King’s College London (20%), and the two academic inventors of CLX001, Martin Ulmschneider and Charles Chen.

24 October 2022
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged


Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram